Tubulointerstitial nephritis associated with treatment with selective Cox-2 inhibitors, celecoxib and rofecoxib;Nefritis tubulointersticial asociada al tratamiento con inhibidores de la Cox-2, celecoxib y rofecoxib

Nefrologia

Volumn 25, Issue 1, 2005, Pages 39-43

  Ortiz, Milagros ^a,c   Mon, C ^a   Fernandez M J ^a   Sanchez R ^a   Alvarez Ude F ^a   Mampaso, F ^b  

^a HOSPITAL GENERAL DE SEGOVIA   (Spain)

^b HOSPITAL RAMÓN Y CAJAL   (Spain)

^c Hospital Universitario de Segovia   (Spain)

Author keywords

Acute and chronic tubulointersticial nephritis; Cox 2 selective inhibitors

Indexed keywords

CELECOXIB; LACTONE; PROSTAGLANDIN SYNTHASE INHIBITOR; PYRAZOLE DERIVATIVE; ROFECOXIB; SULFONAMIDE; SULFONE;

AGED; ARTICLE; CASE REPORT; CHEMICALLY INDUCED DISORDER; FEMALE; HUMAN; INTERSTITIAL NEPHRITIS; PATHOLOGY;

AGED; AGED, 80 AND OVER; CYCLOOXYGENASE INHIBITORS; FEMALE; HUMANS; LACTONES; NEPHRITIS, INTERSTITIAL; PYRAZOLES; SULFONAMIDES; SULFONES;

EID: 20544472687     PISSN: 02116995     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Schlondorff D: Renal complications of nonsteroidal antiinflamatory drugs. Kidney Int 44: 643-653, 1993.
2. Brater DC: Effects of nonsteroidal antiinflamatory drugs on renal funtion focus on cyclooxigenase-2 selective inhibition. Am J Med Dec 13: 107: 655-705, 1999.
3. Whelton A: Nephrotoxicity of nonsteroidal anti-inflamatory drugs: physiologic foundations and clinical implications. Am J Med 106 (5B): 13S-24S, 1999.
4. Simon LS, Weaver SL, Graham DY y cols.: Antiinflamatory and upper gastrointestinal effects of celecoxib in rheumatoids arthritis: A randomiced controlled trial. JAMA 282: 1921-8, 1999.
5. Silverstein FE, Faich G, Goldstein JL y cols.: Gastrointestinal toxicity with celecoxib vs nonsteroidal antiinflamatory drugs for osteoarthritis and rheumatoid arthritis. The Class Study: A randomiced controlled trial. JAMA 284: 1247-55, 2000.
6. Bombardier C, Laine L, Reicin A y cols.: Comparison upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. Vigor Study Group. N Engl J Med 343: 1520-8, 2000.
7. Langman MJ, Jensen DM, Watson DJ y cols.: Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. JAMA 282: 1929-33, 1999.
8. Lipsky PE, Brooks P, Crofford LJ y cols.: Unresolved issues in the role of cyclooxigenasa-2 in normal physiologic processes and disease. Arch Intern Med 160: 913-20, 2000.
9. Khan KNM, Venturini CM, Bunch RT y cols.: Interspecies differences in renal localization of cyclooxigenase isoforms: implications in nonsteroidal antiinflamatory drug related nephrotoxicity. Toxicol Pathol 26: 612-620, 1998.
10. Dinchuck JE, Car BD, Focht RJ y cols.: Renal abnormalities and an altered inflamatory response in mice lacking cyclooxigenase. Nature 378: 406-109, 1995.
11. Morham SG, Laugenbach RL, Loftin CD y cols.: Prostaglandin sythase 2 gene dysruption causes several renal pathology in the mouse. Cell 83: 473-182, 1995.
12. Komhoff M, Wang JL, Cheng HF y cols.: Cyclooxigenase-2 selective inhibitors impair glomerulogenesis and renal cortical development. Kidney Int 57: 414-22, 2000.
13. Harris RC: Cyclooxigenase-2 in the kidney. J Am Soc Nephrol 11: 2387-2394, 2000.
14. Peracella MA, Eras J: Are selective Cox-2 inhibitors nephrotoxic? Am J Kidney Dis 35: 937-940, 2000.
15. Swan SK, Rudy DW, Lancaster KC y cols.: Effect of cyclooxigenase-2 inhibition on renal function in elderly persons receiving a low salt diet. A randomiced, controlled trial. Ann Intern Med 133: 1-9, 2000.
16. Peracella MA, Tray K: Selective cyclooxigenase-2 inhibitors: A pattern of nephrotoxicity similar to traditional nonsteroidal antiinflamatory drugs. Am J Med 111: 64-67, 2001.
17. Dun MJ: Are Cox-2 selective inhibitors nephrotoxic? Am J Kidney disease 35: 976-7, 2000.
18. Whelton A, Maurath CJ, Verburg KM y cols.: Renal safety and tolerability of celecoxib, a novel cyclooxigenase-2 inhibitor. Am J Therap 7: 159-175, 2000.
19. Zhao SZ, Reynolds MW, Lejkowith J, Whelton A, Arellano FM: A comparison of renal related adverse drugs reactions between rofecoxib and celecoxib, based on the World Health Organization/Uppsala Monitoring Centre safety database. Clin Ther 23 (9): 1478-1491, 2001.
20. Clement D: Celecoxib: a review of its use in osteoarthritis, rheumatoid arthritis and acute pain. Drugs 59: 957-982, 2000.
21. Rocha JL, Fernández-Alonso J: Acute tubulointerstitial nephritis associated with the selective Cox-2 enzyme inhibitor, rofecoxib. Lancet 357: 1946-1947, 2001.
22. Alim N, Peterson L, Zimmerman SW, Updike S: Rofecoxib-induced acute interstitial nephritis. Am J Kidney Dis 41: 720-721, 2003.
23. Henao J, Hisamuddin I, Nzerue CM y cols.: Celecoxib-induced acute interstitial nephritis. An J Kidney Dis 39: 1313-1317, 2002.
24. Brewster VC, Perazella MA: Acute tubulointerstitial nephritis associated with celecoxib. Nephrol Dial Transplant 19; 1017-1018, 2004.
25. Alper A B Jr, Meleg-Smith S, Krane NK: Nephrotic syndrome and interstitial nephritis associated with celecoxib. Am J Kidney Dis 40: 1086-90, 2002.
26. Markowitz GS, Falkowitz DC, Isom R y cols.: Membranous glomerulopathy and acute interstitial nephritis following treatment with celecoxib. Clin Nephrol 59 (2): 137-12, 2003.
27. Demke D, Zhaos SZ, Arellano FM: Interstitial nephritis associated with celecoxib. Lancet 358: 1726-1727, 2001.